Tumour suppressor genes play a cardinal role in the development of a large array of human
cancers, including lung cancer, which is one of the most frequently diagnosed cancers …

Non-small cell lung cancer (NSCLC) stages I-III are predominantly treated with surgery and
combination immunotherapy and chemotherapy. A majority of these studies excluded …

The development of acquired resistance to small molecule tyrosine kinase inhibitors (TKIs)
targeting epidermal growth factor receptor (EGFR) signaling has hindered their efficacy in …

Objective To evaluate the impact of sequential (first-to third-generation) epidermal growth
factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment on top corrected QT-interval …

Aim: The present study is to investigate the association between T790M status and clinical
characteristics of patients with EGFR-sensitive advanced non-small cell lung cancer …

Globally, the morbidity and mortality rates of lung cancer are increasing [1], making it a
significant public health concern and burden for families [2]. Approximately 75% of the 2.20 …

Background International guidelines recommend the use of local therapy (LT) to limited
progression in patients with epidermal growth factor receptor (EGFR)-mutated advanced …

The epidermal growth factor receptor (EGFR) has been well validated as a therapeutic target
for anticancer drug discovery. Osimertinib has become the first globally accessible third …

The long non-coding RNA HOTAIR and the Hedgehog-Gli1 signaling pathway are closely
associated with tumor occurrence and drug resistance in various cancers. However, their …

Background TP53 is a frequently mutated oncogene within non-small cell lung cancer
(NSCLC). However, the clinical and prognostic significance of co-mutations in TP53 in …